昊海生科(688366) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥618,542,128.87, a decrease of 4.25% compared to ¥645,995,271.22 in the same period last year[4] - The net profit attributable to shareholders was ¥90,312,072.67, down 7.41% from ¥97,541,532.98 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥88,474,729.61, reflecting a decrease of 7.08% compared to ¥95,217,851.02 in the previous year[4] - Total revenue for Q1 2025 was ¥618.54 million, a decrease of 4.9% compared to ¥645.99 million in Q1 2024[16] - Net profit for Q1 2025 was ¥83.81 million, a decline of 9.4% from ¥92.49 million in Q1 2024[16] - Basic earnings per share for Q1 2025 were ¥0.39, compared to ¥0.42 in Q1 2024[17] Cash Flow - The net cash flow from operating activities increased by 13.04% to ¥85,876,398.75, compared to ¥75,969,702.64 in the same period last year[4] - In Q1 2025, the net cash flow from operating activities was ¥85,876,398.75, an increase of 13.5% compared to ¥75,969,702.64 in Q1 2024[19] - Total cash inflow from operating activities was ¥640,948,930.38, down 9.1% from ¥705,232,753.89 in the previous year[19] - The net cash flow from investing activities was -¥179,294,387.16, a significant decrease from ¥159,290,447.77 in Q1 2024[19] - The net cash flow from financing activities was -¥79,079,486.98, compared to a positive cash flow of ¥42,137,675.19 in Q1 2024[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,127,388,076.14, a slight increase of 0.08% from ¥7,121,392,176.35 at the end of the previous year[5] - Total assets as of March 31, 2025, amounted to ¥7.13 billion, slightly up from ¥7.12 billion at the end of 2024[14] - Total liabilities decreased to ¥1.18 billion as of March 31, 2025, from ¥1.20 billion at the end of 2024[14] - The company’s total equity increased to ¥5.95 billion as of March 31, 2025, from ¥5.92 billion at the end of 2024[14] Research and Development - Research and development expenses totaled ¥48,418,019.42, a decrease of 25.40% from ¥64,900,123.30 year-on-year[4] - Research and development expenses for Q1 2025 were ¥48.42 million, a decrease of 25.5% from ¥64.90 million in Q1 2024[16] - The proportion of R&D expenses to operating revenue was 7.83%, down from 10.05% in the previous year, a reduction of 2.22 percentage points[4] Inventory and Cash Equivalents - The company reported an increase in inventory to ¥488.20 million as of March 31, 2025, compared to ¥490.65 million at the end of 2024[13] - Cash and cash equivalents were ¥2.54 billion as of March 31, 2025, down from ¥2.63 billion at the end of 2024[13] - The total cash and cash equivalents at the end of Q1 2025 were ¥944,673,243.30, an increase from ¥846,192,318.84 in Q1 2024[20] Non-Recurring Gains - The company reported non-recurring gains of ¥1,837,343.06 for the period, primarily from government subsidies and asset disposals[7]